Notably, the serum and urine levels of NGAL progressively increased from the initiation of IRI until the chronic phase of the disease, which remained substantially elevated at day 28 post-ischemia, suggesting that NGAL might be a better biomarker to dynamically monitor AKI-to-CKD progression (Figure 9A). This evidence concerns the gene LCN2 and ischemia.